PFE has apparently reversed itself and now considers cardiovascular medicine a core area of expertise. From Monday’s WSJ interview with CEO, Ian Read: http://online.wsj.com/article/SB20001424052748704473104576293083128749142.html “We've declared a core, which is neuroscience, cardiovascular medicine, oncology, inflammation, immunology and vaccines. We have these three specialized units for pain, sensory disorders and biosimilars.” About 2.5 years ago, PFE said it was withdrawing from R&D in the CV arena: #msg-32523077.